Watch TARA. Know when insiders buy.
One email the day a filing lands. Free.
TARA
Protara Therapeutics, Inc.
3.26
−0.02 −0.61%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $192.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$70MNET CASH $17.1M52W 3.26 – 7.56SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$23.3M | −$21.7M | — | -0.36 | −$15.4M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$19.6M | −$17.8M | — | -0.31 | −$21.3M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$19.1M | −$17.3M | — | -0.38 | −$16.9M | $24K | −$17M | Mar 10 |
| Q3 2025 · Sep 30 | — | — | — | −$14.8M | −$13.3M | — | -0.31 | −$12.5M | $4K | −$12.5M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$16.6M | −$15M | — | -0.35 | −$12.3M | $22K | −$12.3M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$14.1M | −$11.9M | — | -0.29 | −$14.7M | $44K | −$14.8M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$14.3M | −$12.8M | — | -0.43 | −$9.3M | $0 | −$9.3M | Mar 10 |
| Q3 2024 · Sep 30 | — | — | — | −$12.3M | −$11.2M | — | -0.50 | −$8.4M | $8K | −$8.4M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$10.7M | −$9.5M | — | -0.45 | −$7.7M | — | — | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$11.9M | −$11.1M | — | -0.97 | −$10.4M | — | — | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$11M | −$10.2M | — | -0.90 | −$8.7M | $0 | −$8.7M | Mar 5 |
| Q3 2023 · Sep 30 | — | — | — | −$10.7M | −$9.9M | — | -0.87 | −$6.6M | $37K | −$6.6M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$64.5M | −$57.4M | — | -1.34 | −$56.4M | $94K | −$56.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$49.2M | −$44.6M | — | -2.17 | −$35.8M | $63K | −$35.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$43.6M | −$40.4M | — | -3.57 | −$37.6M | $45K | −$37.6M | $91K | — |
| FY2022 · to Dec 31 | — | — | −$67.1M | −$66M | — | -5.86 | −$26.5M | $120K | −$26.6M | $90K | — |
| FY2021 · to Dec 31 | — | — | −$47.5M | −$47.3M | — | -4.21 | −$34.5M | $596K | −$35.1M | $228K | — |
| FY2020 · to Dec 31 | — | — | −$34.4M | −$34M | — | -4.70 | −$23.4M | $884K | −$24.3M | — | — |
Every number comes from Protara Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.